Clinical pathological features and surgical treatment of primary intrahepatic cholangiocarcinoma

Abstract

Lei Daoxiong, Wang Fengbiao, Liu Sen. Clinical pathological features and surgical treatment of primary intrahepatic cholangiocarcinoma[J]. Journal of International Oncology, 2015, 42(1): 60-63.

［1］ Njei B. Intrahepatic cholangiacarcinoma: are we doing the right thing?［J］. Gastrointerst Cancer Res, 2014, 7(1): 1-3. ［2］朱珍, 丛文铭. 肝内胆管细胞癌的临床病理学观察［J］. 临床肝胆病杂志, 2013, 29(1): 42-44. ［3］ Konstadoulakis MM, Roayaie S, Gomatos IP, et al. Fifteenyear, singlecenter experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and longterm outcome［J］. Surgery, 2008, 143(3): 366374. ［4］ Shimada M, Sugimoto K, Iwahashi S, et al. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma［J］. J Gastroenterol, 2010, 45(8): 896-902. ［5］ Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM［J］. Ann Surg Oncol, 2010, 17(6): 14711474. ［6］ Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiacarcinoma［J］. J Hepatol, 2014, 60(6): 1268-1289. ［7］ Brown KM, Parmar AD, Geller DA. Intrahepatic cholangiacarcinoma［J］. Surg Oncol Clin N Am, 2014, 23(2): 231-246. ［8］ Tan JC, Coburn NG, Baxter NN, et al. Surgical management of intrahepatic cholangiocarcinomaa populationbased study［J］. Ann Surg Oncol, 2008, 15(2): 600-608. ［9］ Uenishi T, Kubo S, Yamazaki O, et al. Indications for surgical treatment of intrahepatic cholangiocarcinoma with lymph node metastases［J］. J Hepatobiliary Pancreatic Surg, 2008, 15(4): 417-422. ［10］ Tamandl D, Herberger B, Gruenberger B, et al. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma［J］. Ann Surg Oncol, 2008, 15(10): 2787-2794. ［11］ Ribero D, Pinna AD, Guglielmi A, et al. Surgical approach for longterm survival of patients with intrahepatic cholangiocarcinoma: a multiinstitutional analysis of 434 patients［J］. Arch Surg, 2012, 147(12): 1107-1113. ［12］ Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection［J］. Ann Surg, 2008, 248(1): 84-96. ［13］ Choi SB, Kim KS, Choi JY, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival［J］. Ann Surg Oncol, 2009, 16(11): 3048-3056. ［14］ Hyder O, Hatzaras I, Sotiropoulos GC, et al. Recurrence after operative management of intrahepatic cholangiocarcinoma［J］. Surgery, 2013, 153(6): 811-818. ［15］ Fu BS, Zhang T, Li H, et al. The role of liver transplantation for intrahepatic cholangiocarcinoma: a singlecenter experience［J］. Eur Surg Res, 2011, 47(4): 218221. ［16］ Wolfe RA, Roys EC, Merion RM. Trends in organ donation and transplantation in the United States, 19992008［J］. Am J Transplant, 2010, 10(4): 961-972. ［17］ Hong JC, Jones CM, Duffy JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24year experience in a single center［J］. Arch Surg, 2011, 146(6): 683-689. ［18］ Sapisochin G, Rodriguez de Lope C, Gastaca M, et al. "Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients?［J］. Am J transplant, 2014, 14(3): 660-667. ［19］ Gusani NJ, Balaa FK, Steel JL, et al. Treatment of unresectable cholangiocarcinoma with gemcitabinebased transcatheter arterial chemoembolization (TACE): a singleinstitution experience［J］. J Gastrointest Surg, 2008, 12(1): 129-137. ［20］ Jarnagin WR, Schwartz LH, Gultekin DH, et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase Ⅱ clinical trial and assessment of DCEMRI as a biomarker of survival［J］. Ann Oncol, 2009, 20(9): 1589-1595. ［21］ Kiefer MV, Albert M, McNally M, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2center study［J］. Cancer, 2011, 117(7): 1498-1505. ［22］ Hoffmann RT, Paprottka PM, Schon A, et al. Transarterial hepatic yttrium90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival［J］. Cardiovasc Intervent Radiol, 2012, 35(1): 105-116. ［23］ Kim JH, Won HJ, Shin YM, et al. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma［J］. AJR Am J Roentgenol, 2011, 196(2): W205-209. ［24］ Fu Y, Yang W, Wu W, et al. Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma［J］. J Vasc Intervent Radiol, 2012, 23(5): 642-649. ［25］ Sia D, Tovar V, Moeini A, et al. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies［J］. Oncogene, 2013, 32(41): 4861-4870. ［26］ Bengala C, Bertolini F, Malavasi N, et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase Ⅱ trial［J］. Br J Cancer, 2010, 102(1): 68-72. ［27］ Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliarytract cancers and correlation of changes in 18fluorodeoxyglucose PET with clinical outcome: a phase 2 study［J］. Lancet Oncol, 2010, 11(1): 4854. ［28］ Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study［J］. Lancet Oncol, 2010, 11(12): 1142-1148. ［29］ Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliarytract cancer: a multicentre, openlabel, randomised, phase 3 study［J］. Lancet Oncol, 2012, 13(2): 181-188.

[1]	Huang Hui, Ding Jianghua.Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma[J]. Journal of International Oncology, 2023, 50(9): 569-573.
[2]	Zhou Weiwen, Sun Xiaonan.Research progress of radiotherapy in extrahepatic cholangiocarcinoma[J]. Journal of International Oncology, 2020, 47(7): 431-435.
[3]	Zhang Yu, Xu Bin, Wang Dongmei.Curative effect analysis of 3DCRT combined with thalidomide and GEMOX regimen in advanced intrahepatic cholangiocarcinoma[J]. Journal of International Oncology, 2019, 46(5): 262-266.
[4]	Xue Dong, Xia Xiuliang, Song Dekun, Xiang Tinghai, Wang Jianqiang, Gong Bengang.Expression and clinical significance of cullin 4A in cholangiocarcinoma[J]. Journal of International Oncology, 2019, 46(3): 153-156.
[5]	Ni Chuandou, Song Chunfeng, Yang Mingjun, Xing Peng, Zhang Wei.Progress in the study of preoperative evaluation and surgical treatment of hilar cholangiocarcinoma[J]. Journal of International Oncology, 2018, 45(11): 692-695.
[6]	Zou Rongji, Ma Qingjiu.Research progress on body fluids microRNAs in the diagnosis of cholangiocarcinoma[J]. Journal of International Oncology, 2017, 44(4): 300-303.
[7]	Wu Xiongbo, An Fangmei, Zhan Qiang.MicroRNAs： the emerging regulatory molecules and biomarkers of cholangiocarcinoma[J]. Journal of International Oncology, 2016, 43(11): 865-867.
[8]	Luo Mengchao, Ding Chaofeng, Wu Jian, Zheng Shusen.Treatment progress of intrahepatic cholangiocarcinoma[J]. Journal of International Oncology, 2016, 43(1): 60-63.
[9]	Guo Jianyang, Liu Xia, Liao Rui, Du Chengyou.Progress of radiotherapy for hilar cholangiocarcinoma[J]. Journal of International Oncology, 2014, 41(5): 350-353.

Clinical pathological features and surgical treatment of primary intrahepatic cholangiocarcinoma

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles9

Recommended Articles

Metrics

Comments